Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1792, Issue 7, Pages 625-633Publisher
ELSEVIER
DOI: 10.1016/j.bbadis.2008.09.015
Keywords
Leucine-rich repeat kinase 2; Dardarin; Neurodegeneration; Kinase; Movement disorder; Molecular genetic
Funding
- NINDS NIH HHS [R00 NS058111-03, R00 NS058111] Funding Source: Medline
Ask authors/readers for more resources
The frequency and potency of mutations in the LRRK2 gene redefine the role of genetic susceptibility in Parkinson's disease. Dominant missense mutations that fulfill initial criteria for potential gain of function mechanisms coupled with enzymatic activity likely amenable to small molecule inhibition position LRRK2 as a promising therapeutic target. Herein, key observations from the clinic to the test tube are highlighted together with points of contention and outstanding critical issues. Resolution of the critical issues will expedite the development of therapies that exploit LRRK2 activity for neuroprotection strategies. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available